RayzeBio, Inc.
RYZBDelisted Feb 26, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001825367
RayzeBio, Inc. was delisted on Feb 26, 2024; its insiders filed their last Form 4 on Feb 28, 2024; 107 institutions reported holding it in 13F filings for Q4 2023, worth $3.40B in total; superinvestors Viking Global Investors and HHLR Advisors (Hillhouse) held it.
Superinvestors holding RYZB, Q4 2023
2 superinvestors report holding RayzeBio, Inc. on Form 13F, worth $479.0M in total. Weight is RayzeBio, Inc.'s share of each 13F portfolio; actions compare shares with Q3 2023.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| Viking Global InvestorsAndreas Halvorsen | 1.5% | 6,642,700 | $413.0M | Unchanged |
| HHLR Advisors (Hillhouse)Zhang Lei | 1.3% | 1,062,383 | $66.0M | Reduced−23.9% |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of RYZB each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q4 2023
2 superinvestors holding at quarter end
- Reduced
- HHLR Advisors (Hillhouse) (−23.9%)
- Sold out
- Soros Fund Management
Q3 2023
3 superinvestors holding at quarter end